Ipca Laboratories (IPCALAB) Q3 24/25 earnings summary

Executive summary

• Domestic formulation business grew 13% for the quarter, outpacing the market and ranking 16th by IQVIA, fastest among top 20 players.

• Market share improved by 11 basis points to 2.05% as of December 2024.

• Six brands are among the top 300 in India, with strong performance in both acute and chronic segments.

• Standalone net total income for Q3 FY25 rose 10% year-over-year to Rs. 1,680.09 crores; consolidated net total income up 9% to Rs. 2,265.48 crores.

• Standalone net profit for Q3 FY25 increased 95% year-over-year to Rs. 267.56 crores; consolidated net profit up 38% to Rs. 248.14 crores.

Financial highlights

• Standalone Q3 FY25 EBITDA margin reached 24.25%, up from 18.52% in Q3 FY24; consolidated Q3 FY25 EBITDA margin at 19.87%, up from 16.1%.

• Gross margin hit a record high, driven by improved product mix and higher ROW market business, with material cost ratio dropping to 27.62% in Q3.

• API business grew 12% for the quarter; overall formulation business grew 6%.

• Pain management portfolio grew 14% in the first nine months; overall domestic portfolio grew 12%.

• Standalone EPS for Q3 FY25 was Rs. 10.55 (after exceptional items), up 95% year-over-year; consolidated EPS was Rs. 9.78, up 38%.

Outlook and guidance

• Standalone and consolidated EBITDA margins expected to remain above guidance for FY25, in the 23%-24% and 19.18%-19.5% ranges, respectively.

• API business projected to grow 8%-10% going forward.

• Domestic business expected to grow at 1.5x the Indian pharma market (IPM) rate over the next 2-3 years.

• Margins expected to improve by 100-150 basis points over the next 3-4 years due to operational leverage and productivity gains.

• Management notes that the acquisition of Unichem Laboratories Ltd. in August 2023 impacts year-over-year comparability for the nine-month period.